Merck (MRK.US) Q3 results beat expectations: Keytruda and Gardasil deliver strong performance, full-year guidance raised.

Zhitong Finance APP has learned that Merck (MRK.US) announced its third-quarter 2026 results. Q3 total revenue was US$18.085 billion, up 5% year over year (4% excluding the impact of foreign exchange), above the average analyst estimate of US$17.31 billion compiled by LSEG; adjusted earnings per share were US$2.49, far exceeding the expected US$2.08; net profit under GAAP was US$5.065 billion, with earnings per share of US$2.04, both down 12% year over year. The company also raised its full-year guidance the same day: the low end of the 2026 revenue range was raised from US$66.3 billion to US$66.8 billion, and the full-year adjusted earnings per share guidance was raised from US$2.662.76 to US$2.772.82.